Market Research Logo

Community Acquired Pneumonia - Pipeline Review, H1 2015

Community Acquired Pneumonia - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Community Acquired Pneumonia - Pipeline Review, H1 2015’, provides an overview of the Community Acquired Pneumonia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Community Acquired Pneumonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Community Acquired Pneumonia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Community Acquired Pneumonia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Community Acquired Pneumonia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Community Acquired Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Community Acquired Pneumonia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Community Acquired Pneumonia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Community Acquired Pneumonia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Community Acquired Pneumonia Overview
Therapeutics Development
Pipeline Products for Community Acquired Pneumonia - Overview
Pipeline Products for Community Acquired Pneumonia - Comparative Analysis
Community Acquired Pneumonia - Therapeutics under Development by Companies
Community Acquired Pneumonia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Community Acquired Pneumonia - Products under Development by Companies
Community Acquired Pneumonia - Companies Involved in Therapeutics Development
Actavis plc
AstraZeneca PLC
Biotest AG
C10 Pharma AS
Kyorin Pharmaceutical Co., Ltd.
Paratek Pharmaceuticals, Inc.
TaiGen Biotechnology Co., Ltd.
Takeda Pharmaceutical Company Limited
Community Acquired Pneumonia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BT-086 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRPAM-1977X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nemonoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omadacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for SSTI and CAP Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ticagrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Community Acquired Pneumonia - Recent Pipeline Updates
Community Acquired Pneumonia - Dormant Projects
Community Acquired Pneumonia - Discontinued Products
Community Acquired Pneumonia - Product Development Milestones
Featured News & Press Releases
Oct 03, 2014: FDA Grants Durata Therapeutics a Special Protocol Agreement for Its Phase 3 Study of DALVANCE in Hospitalized Community-Acquired Pneumonia
Sep 11, 2013: New Antibiotic Shows Promise for Treating MRSA Pneumonia
May 16, 2013: TaiGen Biotechnology Submits New Drug Application For Nemonoxacin In Taiwan And China
Aug 28, 2012: European Commission Approves Zinforo To Treat Skin Infections Or Community Acquired Pneumonia
Jun 22, 2012: CHPM Adopts Positive Opinion For Zinforo For Treatment Of Complicated Skin And Soft Tissue Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Community Acquired Pneumonia, H1 2015
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Community Acquired Pneumonia - Pipeline by Actavis plc, H1 2015
Community Acquired Pneumonia - Pipeline by AstraZeneca PLC, H1 2015
Community Acquired Pneumonia - Pipeline by Biotest AG, H1 2015
Community Acquired Pneumonia - Pipeline by C10 Pharma AS, H1 2015
Community Acquired Pneumonia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015
Community Acquired Pneumonia - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015
Community Acquired Pneumonia - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015
Community Acquired Pneumonia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Community Acquired Pneumonia Therapeutics - Recent Pipeline Updates, H1 2015
Community Acquired Pneumonia - Dormant Projects, H1 2015
Community Acquired Pneumonia - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Community Acquired Pneumonia, H1 2015
Number of Products under Development for Community Acquired Pneumonia - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report